Difference between revisions of "Part:BBa K2549005"
m
Line 3: Line 3:
 
<partinfo>BBa_K2549005 short</partinfo>
 
<partinfo>BBa_K2549005 short</partinfo>
  
−
Anti-CD19 (&#945;CD19) is a CD19 scFv. Its heavy-chain variable region (&#945;CD19a) and light-chain variable region (&#945;CD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S for short)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>. It was used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19 (surCD19 was used in our project, [[Part:BBa_K2549001]]).  
+
Anti-CD19 (&#945;CD19) is a CD19 scFv. Its heavy-chain variable region (&#945;CD19a) and light-chain variable region (&#945;CD19b) are fused using a glycine-rich peptide linker (3 repeats of GGGGS, or G4S for short)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>. It was used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19 (surCD19 was used in our project, [[Part:BBa_K2549001]]).  
  
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>

Revision as of 05:25, 7 October 2018


anti-CD19

Anti-CD19 (αCD19) is a CD19 scFv. Its heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) are fused using a glycine-rich peptide linker (3 repeats of GGGGS, or G4S for short)[1]. It was used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19 (surCD19 was used in our project, Part:BBa_K2549001).

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 444


Usage and Biology

TBA



References

  1. ↑ Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005